A generic and immunological investigation of JAK-STAT in the pathogenesis of Celiac
JAK-STAT 在乳糜泻发病机制中的一般和免疫学研究
基本信息
- 批准号:10615604
- 负责人:
- 金额:$ 16.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAgonistAtrophicAutoimmune DiseasesBioinformaticsBiologicalBiological AssayCD4 Positive T LymphocytesCeliac DiseaseCellular biologyChromosome 21ClinicalClinical DataCytotoxic T-LymphocytesDatabasesDevelopmentDevelopment PlansDiseaseDown SyndromeExhibitsGastrointestinal DiseasesGene DosageGene Expression ProfileGeneral PopulationGenesGeneticGenetic DeterminismGenetic DiseasesGenetic ScreeningGerm LinesGlutenGluten-free dietGoalsHLA-DQ2HLA-DQ8 antigenHelper-Inducer T-LymphocyteHumanHuman Subject ResearchIFNAR1 geneIFNAR2 geneIFNGR2 geneIL10RB geneImmuneImmunityImmunologicsImmunologyImpairmentIndividualInflammatoryInheritedInsulin-Dependent Diabetes MellitusInterferon ReceptorInterferon Type IIInterferon alphaInterferonsInterleukin-15InternationalInvestigationKnowledge acquisitionLaboratoriesLeadLibrariesMeasuresMediatingMentorsMolecularMolecular ProfilingMutationPathogenesisPathway interactionsPatientsPatternPharmaceutical PreparationsPhenocopyPhenotypePhosphorylationPhysiciansPredispositionProductionProliferatingRNAReceptor GeneReportingResearchResearch PersonnelRiskRoleSTAT1 geneSTAT3 geneSamplingScientistSerumSeveritiesSignal TransductionSortingT-Cell DevelopmentT-LymphocyteTestingThyroiditisTrainingTraining ProgramsTranscriptTransducersTranslational ResearchWorkadaptive immunitycareercareer developmentclinical investigationclinical phenotypeclinically significantcohortcytokinedesignexome sequencinggain of functiongenetic approachgenetic risk factorgenetic varianthigh riskindexinginhibitorinterleukin-21intestinal villimonocytepatient orientedpermissivenessreceptorrecruitresearch and developmentresponsescreeningsingle-cell RNA sequencingskillstherapeutic targettranscription factortranscriptome sequencing
项目摘要
The proposal details a comprehensive five years training program to expand my skills as a physician-scientist.
The research plan is focused on JAK-STAT pathway in Celiac Disease (CeD), but the training plan includes
extensive didactics in human subject research, bioinformatics and laboratory-based training on T cell
immunology. CeD is an immune mediated gastrointestinal disease that arises in patients with a permissive
HLA-DQ2/HLA-DQ8 genetic background. The only available treatment for CeD is to follow a gluten-free diet.
Patients with germline gain-of-function (GOF) STAT3 mutations and Down Syndrome have an estimated 40-
fold and 5-fold higher risk of CeD, respectively, than the general population, along with a predisposition for
other autoimmune diseases, including thyroiditis and Type I Diabetes. Patients with Down Syndrome have
three copies of the gene for interferon (IFN) receptors on chromosome 21 and thus constitutive JAK-STAT
activation. The central hypothesis is that interferon and cytokines mediated JAK-STAT overactivation may
cause loss of T cell tolerance to gluten and an increased risk for CeD. The overall goal of this research is to
investigate the mechanism of JAK-STAT activation in the pathogenesis of CeD. To accomplish this, first, we
will conduct genetic investigation in 100 index cases with familial CeD and search for genetic variants in the
JAK-STAT pathway. We will also expand our cohort of CeD patients with known genetic diseases affecting
JAK-STAT activation, include patients with GOF-STAT3 and DS. Second, we will assess the key molecules in
the JAK-STAT pathway, including agonists, receptors, STAT and their phosphorylated forms, ISGs in
monocyte and CD4+ T cells to identify a molecular signature of active CeD. Third, we will investigate the
mechanisms of JAK-STAT overactivation on gluten-specific CD4+ T cells through both single cell RNA-Seq and
amplified T cell libraries, followed by testing the functional impact of JAK inhibitors on gluten-specific T cells.
The results of this study will delineate JAK-STAT activation and its potential as a therapeutic target for Celiac
Disease. Furthermore, through the proposed complementary career development plan, I will gain additional
training in clinical investigation on the genetics and immunology of CeD; advanced bioinformatic analysis with
RNA-seq; and laboratory-based training in gluten specific CD4+ T cells biology. Throughout this research and
career development activities, I will be mentored by a team lead by Dr. Timothy Wang, an internationally
recognized physician-scientist and an expert in inflammatory cytokines and their role in human gastrointestinal
diseases. I am committed to a career as an independent investigator in patient-oriented translational research;
and have designed my training plan to acquire the knowledge and skills needed to make a meaningful and
substantial contribution to the field by using a functional genetics approach to discover the therapeutic targets
in gastrointestinal diseases.
该提案详细介绍了一个全面的五年培训计划,以扩大我作为一名医生科学家的技能。
该研究计划的重点是JAK-STAT途径在乳糜泻(CeD),但培训计划包括
在人类受试者研究、生物信息学和T细胞实验室培训方面的广泛教学
免疫学CeD是一种免疫介导的胃肠道疾病,
HLA-DQ 2/HLA-DQ 8遗传背景。CeD唯一可用的治疗方法是遵循无麸质饮食。
具有生殖系功能获得性(GOF)STAT 3突变和唐氏综合征的患者估计有40-
CeD的风险分别是一般人群的1倍和5倍,
其他自身免疫性疾病,包括甲状腺炎和I型糖尿病。唐氏综合症患者
21号染色体上干扰素(IFN)受体基因的三个拷贝,因此是组成型JAK-STAT
activation.中心假设是干扰素和细胞因子介导的JAK-STAT过度激活可能
导致T细胞对麸质的耐受性丧失,并增加CeD的风险。本研究的总体目标是
探讨JAK-STAT激活在CeD发病中的作用机制。为此,首先,我们
将对100例家族性CeD索引病例进行遗传调查,并在
JAK-STAT途径。我们还将扩大我们的CeD患者队列,这些患者患有已知的遗传疾病,
JAK-STAT激活,包括GOF-STAT 3和DS患者。其次,我们将评估
JAK-STAT途径,包括激动剂、受体、STAT及其磷酸化形式、ISG,
单核细胞和CD 4 + T细胞来鉴定活性CeD的分子特征。第三,我们将调查
JAK-STAT在谷蛋白特异性CD 4 + T细胞上过度活化的机制通过单细胞RNA-Seq和
扩增的T细胞文库,然后测试JAK抑制剂对谷蛋白特异性T细胞的功能影响。
本研究的结果将描述JAK-STAT激活及其作为乳糜泻治疗靶点的潜力。
疾病此外,通过拟议的补充职业发展计划,我将获得额外的收益
CeD遗传学和免疫学临床研究培训;高级生物信息学分析,
RNA-seq;以及基于实验室的谷蛋白特异性CD 4 + T细胞生物学培训。在整个研究过程中,
职业发展活动,我将由Timothy Wang博士领导的团队指导,
他是公认的医生-科学家,也是炎症细胞因子及其在人类胃肠道疾病中作用的专家。
疾病我致力于作为一个独立的研究者在以病人为导向的转化研究的职业生涯;
并设计了我的培训计划,以获得所需的知识和技能,使一个有意义的,
通过使用功能遗传学方法来发现治疗靶点,
in gastrointestinal胃肠diseases疾病.
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The diagnostic yield of exome sequencing in liver diseases from a curated gene panel.
- DOI:10.1038/s41598-023-42202-1
- 发表时间:2023-12-06
- 期刊:
- 影响因子:4.6
- 作者:
- 通讯作者:
Serological Investigation of Persistent Villous Atrophy in Celiac Disease.
- DOI:10.14309/ctg.0000000000000639
- 发表时间:2023-12-01
- 期刊:
- 影响因子:3.6
- 作者:
- 通讯作者:
Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence.
- DOI:10.2147/jir.s280953
- 发表时间:2021
- 期刊:
- 影响因子:4.5
- 作者:Chung H;Green PHR;Wang TC;Kong XF
- 通讯作者:Kong XF
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xiao-Fei Kong其他文献
Xiao-Fei Kong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xiao-Fei Kong', 18)}}的其他基金
A generic and immunological investigation of JAK-STAT in the pathogenesis of Celiac
JAK-STAT 在乳糜泻发病机制中的一般和免疫学研究
- 批准号:
10716065 - 财政年份:2021
- 资助金额:
$ 16.55万 - 项目类别:
A genetic and immunological investigation of JAK-STAT in the pathogenesis of Celiac Disease
JAK-STAT 在乳糜泻发病机制中的遗传和免疫学研究
- 批准号:
10191231 - 财政年份:2021
- 资助金额:
$ 16.55万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 16.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 16.55万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别: